Other studies have investigated antithrombotic therapy for stable coronary artery disease and AF, but AQUATIC is the first double blinded, placebo controlled, randomized trial to include patients who had prior stenting and a high atherothrombotic risk. Of note, the risk of events was 7 to 8 higher in AQUATIC than in previous trials in the field.
